3rd International AIDS Society Conference on HIV Pathogenesis and Treatment Rio de Janeiro - July 24 - 27, 2005

PREPARATION FOR VACCINE EFFICACY TRIALS: BASELINE PREVALENCE, ESTIMATES OF INCIDENCE AND DEMOGRAPHIC RISK FACTORS IN POPULATIONS WILLING TO RECEIVE VOLUNTARY COUNSELING AND TESTING AND PARTICIPATE IN RESEARCH IN UGANDA AND KENYA

IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd: Abstract No. WePp0204

Ketter N.¹, Kamali A.², Sanders E.³, Katende M.⁴, Anzala O.⁵, Von Lieven A.⁶, Price M.¹, Stevens G.⁷, Stoll L.¹, Gilmour J.8, Thomson H.⁶, Kambili C.⁶, Fast P.^8
1 International AIDS Vaccine Initiative, San Mateo, United States of America, ² Medical Research Council, Masaka, Uganda, ³ Centers for Geographic Medicine, Coast, Kilifi, Kenya, ⁴ Joint Clinical Research Center, Kakira, Uganda, ⁵ Kenya AIDS Vaccine Initiative, Nairobi, Kenya, ⁶ International AIDS Vaccine Initiative, Nairobi, Kenya, ⁷ International AIDS Vaccine Initiative, Johannesburg, South Africa, ⁸ International AIDS Vaccine Initiative, New York, United States of America

OBJECTIVES: To prepare clinical trial sites and develop capacity by conducting research to obtain baseline prevalence, estimates of incidence and risk factors in populations willing to receive voluntary counseling and testing (VCT) at four sites in Uganda and Kenya.

METHODS: Four sites, selected for development as potential HIV vaccine efficacy trial sites, were provided community education, developed field mobile/static research VCT clinics conducted a cross sectional survey of HIV prevalence in volunteers aged 18-60 yearsRisk factor and demographic data were collected. Viral typing and the BED assay to obtain estimates of incidence are in progress.

RESULTS: Between January and December 2004, 6,463 volunteers who were willing to have VCT were recruited at four sites. The prevalence data, by gender, is summarized:

At all sites HIV prevalence peaked in the mid 30's. Women became infected more frequently and at younger ages with the greatest slope between 18 and 30 years of age.

CONCLUSIONS: Conduct of this prevalence study has prepared the community for research and VCT in addition to providing some baseline demographic and risk data that will allow for the selection of subgroups of potential volunteers at higher risk for HIV vaccine efficacy trials and strengthen referral networks for prevention and care.

Download PDF of this abstract.

050724
Prevention | WePp0204 | Nzeera Ketter
Planning For Vaccine Efficacy Trials

Copyright © 2005 - International AIDS Society (IAS). All information and content relating to the abstracts from the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment, such as text, graphics, logos, button icons, images, audio clips, and software is protected by copyright. Permission is hereby granted for the non-commercial use or reproduction of the information on this web site, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.

AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. Permission is hereby granted for the non-commercial use or reproduction of the information herein, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.